reless



AC/WDN:gte 10/15/04 PATENT

Attorney Reference Number 4239-64828-02 Express Mail Label No. EV514604915US Date of Deposit: October 15, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Blackshear et al.

Application No. Not yet assigned

Filed: Herewith

Confirmation No. Not yet assigned

For: COMPOSITIONS AND METHODS FOR

DIAGNOSTICS AND THERAPEUTICS FOR

HYDROCEPHALUS

Examiner: Not yet assigned Art Unit: Not yet assigned

Attorney Reference No. 4239-64828-02

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as Express Mail Label No. EV514604915US in an envelope addressed to: MAIL STOP PCT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

...

Agent

for Applicant(s)

Date Mailed October 15, 2004

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(2)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A duplicate copy of the transmittal sheet for this IDS is enclosed.

Rec'd PCT/PTO 1 4 OCT 2004

AC/WDN:gte 10/15/04 **PATENT**

Attorney Reference Number 4239-64828-02 Express Mail Label No. EV514604915US Date of Deposit: October 15, 2004

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

Anne Carlson, Ph.D.

Registration No. 47,472

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446

AC/WDN:gte 10/15/04 317615.doc PATENT

10/511362 DT05 Rec'd PCT/PT0 14 OCT 2004 Atteney Reference Number 4239-64828-02 ess Mail Label No. EV514604915US Date of Deposit: October 15, 2004

			Attorney Docket Number	4239-64828-02	
		Application Number	Not yet assigned		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filed	Herewith	
			First Named Inventor	Blackshear	
			Art Unit	Not yet assigned	
			Examiner Name	Not yet assigned	
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS			
		BRÜMMENDORF et al., "Neural cell recognition molecule L1: from cell biology to human hereditary brain malformations," Current Opinion in Neurobiology 8:87-97, 1998			
		GAJIWALA et al., "Structure of the winged-helix protein hRFX1 reveals a new mode of DNA binding," Nature, 403:916-921, 2000			
		MOROTOMI-YANO et al., "Human Regulatory Factor X 4 (RFX4) Is a Testis-specific			
		Dimeric DNA-binding Protein That Cooperates with Other Human RFX Members," J.			
		Biol. Chem. 277(1):836-842, 2002			
		PÉREZ-FÍGARES et al., "Subcommissural Organ, Cerebrospinal Fluid Circulation, and Hydrocephalus," Microscopy Research and Technique 52:591-607, 2001			
		Tij drooophdras, Titoroscopy Resea	uen una Teennique 32.391-0	57, 2001	
		GenBank Accession No. AF332192	2, 11 March 2001		
		GenBank Accession No. BAC2859	8, 5 Dec. 2002		
		GenBank Accession No. NM_0324	91, 6 April 2003		
		GenBank Accession No. NP_00291	1, 6 April 2003		
		GenBank Accession No. NT_00972	20, 8 May 2002		
		GenBank Accession No. XP_12579	97, 24 Feb. 2003		

EXAMINER	DATE
SIGNATURE:	CONSIDERED:

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.